What's in Center for Vulvovaginal Disorders's pipeline?

Center for Vulvovaginal Disorders has 5 drugs in our index: 2 marketed, 0 filed, 0 in Phase 3, 3 in Phase 2, 0 in Phase 1.

Which companies overlap with Center for Vulvovaginal Disorders's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/center-for-vulvovaginal-disorders.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Center for Vulvovaginal Disorders — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Center for Vulvovaginal Disorders pipeline: 2 marketed, 0 filed, 0 Phase 3, 3 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 3 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Intrarosa	Intrarosa	marketed		Corticosteroid-binding globulin, Beta-glucuronidase, Glucose-6-phosphate 1-dehydrogenase	Immunology
clobetasol 0.05% cream	clobetasol 0.05% cream	marketed

Therapeutic area mix

Immunology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Center for Vulvovaginal Disorders:

Cite this brief

Drug Landscape (2026). Center for Vulvovaginal Disorders — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/center-for-vulvovaginal-disorders. Accessed 2026-05-16.